Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia
Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility. Bromo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2013-09-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/3347/21-%205803_E(C)_F(T)_PF1(Pr._P)_PFA(P.r_P)pdf.pdf |
| Summary: | Introduction: Bromocriptine, an ergot derivative, is an agonist
at the dopamine 2 receptor and a sympatholytic. It is a well
established drug in Parkinsonism, hyperprolactinaemia and
acromegaly and it has various other clinical indications like
induction of ovulation in female infertility. Bromocriptine has
been evaluated in alloxan induced diabetic rats for its antihyperglycaemic effect with and without simultaneous use of
glipizide.
Methods: Diabetes was induced in albino rats by giving a single
subcutaneous injection of alloxan in a dose of 150 mg/kg body
weight. After 72 hours of giving alloxan injection, depending
upon their blood glucose levels (350mg/dl and above), the rats
were included into the study and they were divided into four
groups, each comprising of 6 rats (n=24): Group 1 which was
taken as control was given distilled water. Group 2 was treated
with glipizide, a standard drug. Group 3 was treated with the test
drug, bromocriptine and Group 4 was treated with sub therapeutic
doses of test and standard drugs. The drugs were given to the
diabetic rats once daily by oral route for 30 consecutive days,
in order to assess their effects in terms of reduction in blood
glucose levels. Blood glucose was estimated on 0th, 10th, 20th and
30th days of the study at fixed time intervals.
Results and Conclusion: Bromocriptine, which was used alone,
lowered the blood glucose levels appreciably; whereas the
concomitant administration of bromocriptine and glipizide in sub
therapeutic doses produced a much more appreciable reduction.
The results which were obtained in the group which received
simultaneous administration of test and standard drugs in sub
therapeutic doses were comparable to those of the group which
received reference drug, glipizide. Hence, it can be concluded
that bromocriptine may serve as a valuable adjunct to available
anti-diabetic medication. |
|---|---|
| ISSN: | 2249-782X 0973-709X |